Cyclacel Pharmaceuticals (CYCC) announced that it has received a letter from Nasdaq, informing the company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYCC: